Compare Cadila Healthcare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZYDUS LIFESCIENCES vs CIPLA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ZYDUS LIFESCIENCES CIPLA ZYDUS LIFESCIENCES/
CIPLA
 
P/E (TTM) x 17.5 29.4 59.5% View Chart
P/BV x 2.8 4.1 67.7% View Chart
Dividend Yield % 1.0 0.5 184.7%  

Financials

 ZYDUS LIFESCIENCES   CIPLA
EQUITY SHARE DATA
    ZYDUS LIFESCIENCES
Mar-21
CIPLA
Mar-21
ZYDUS LIFESCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs509879 58.0%   
Low Rs259411 63.0%   
Sales per share (Unadj.) Rs147.5237.6 62.1%  
Earnings per share (Unadj.) Rs20.929.8 70.1%  
Cash flow per share (Unadj.) Rs28.043.0 65.0%  
Dividends per share (Unadj.) Rs3.505.00 70.0%  
Avg Dividend yield %0.90.8 117.5%  
Book value per share (Unadj.) Rs126.9226.7 56.0%  
Shares outstanding (eoy) m1,023.74806.46 126.9%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.62.7 95.9%   
Avg P/E ratio x18.421.6 84.9%  
P/CF ratio (eoy) x13.715.0 91.6%  
Price / Book Value ratio x3.02.8 106.4%  
Dividend payout %16.816.8 99.8%   
Avg Mkt Cap Rs m393,092519,826 75.6%   
No. of employees `000NANA-   
Total wages/salary Rs m22,54832,518 69.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m151,022191,596 78.8%  
Other income Rs m4492,698 16.6%   
Total revenues Rs m151,471194,294 78.0%   
Gross profit Rs m31,33542,487 73.8%  
Depreciation Rs m7,24810,677 67.9%   
Interest Rs m1,6881,607 105.0%   
Profit before tax Rs m22,84832,901 69.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4728,888 16.6%   
Profit after tax Rs m21,37624,013 89.0%  
Gross profit margin %20.722.2 93.6%  
Effective tax rate %6.427.0 23.8%   
Net profit margin %14.212.5 112.9%  
BALANCE SHEET DATA
Current assets Rs m87,160132,095 66.0%   
Current liabilities Rs m78,61345,916 171.2%   
Net working cap to sales %5.745.0 12.6%  
Current ratio x1.12.9 38.5%  
Inventory Days Days3368 49.2%  
Debtors Days Days767 1,151.4%  
Net fixed assets Rs m140,943116,277 121.2%   
Share capital Rs m1,0241,613 63.5%   
"Free" reserves Rs m128,899181,232 71.1%   
Net worth Rs m129,923182,844 71.1%   
Long term debt Rs m6,09512,028 50.7%   
Total assets Rs m228,103248,372 91.8%  
Interest coverage x14.521.5 67.7%   
Debt to equity ratio x00.1 71.3%  
Sales to assets ratio x0.70.8 85.8%   
Return on assets %10.110.3 98.0%  
Return on equity %16.513.1 125.3%  
Return on capital %18.017.7 101.9%  
Exports to sales %031.3 0.0%   
Imports to sales %10.510.9 96.5%   
Exports (fob) Rs mNA59,951 0.0%   
Imports (cif) Rs m15,91120,911 76.1%   
Fx inflow Rs m63,53568,051 93.4%   
Fx outflow Rs m15,91120,911 76.1%   
Net fx Rs m47,62447,140 101.0%   
CASH FLOW
From Operations Rs m32,93037,552 87.7%  
From Investments Rs m-7,225-23,872 30.3%  
From Financial Activity Rs m-25,489-13,299 191.7%  
Net Cashflow Rs m-905509 -177.8%  

Share Holding

Indian Promoters % 74.9 13.5 555.1%  
Foreign collaborators % 0.0 20.1 -  
Indian inst/Mut Fund % 15.4 48.6 31.7%  
FIIs % 2.5 26.6 9.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.1 66.4 37.8%  
Shareholders   408,017 418,584 97.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ZYDUS LIFESCIENCES With:   SUN PHARMA    LUPIN    DR. REDDYS LAB    AUROBINDO PHARMA    PIRAMAL ENTERPRISES    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Cipla Shares Tank Despite Strong Earnings (Views On News)

Aug 6, 2021

The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ZYDUS LIFESCIENCES SHARE PRICE


Jun 24, 2022 (Close)

TRACK ZYDUS LIFESCIENCES

  • Track your investment in ZYDUS LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ZYDUS LIFESCIENCES

ZYDUS LIFESCIENCES 5-YR ANALYSIS

COMPARE ZYDUS LIFESCIENCES WITH

MARKET STATS